Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Endometrial cancer; Oesophageal cancer; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms MIME-A
- 08 Feb 2019 Status changed from not yet recruiting to recruiting.
- 26 Nov 2018 Planned initiation date changed from 1 Dec 2018 to 15 Dec 2018.
- 12 Sep 2018 Planned initiation date changed from 15 Feb 2018 to 1 Dec 2018.